Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
10x Genomics (Nasdaq: TXG) reported preliminary, unaudited select results for Q4 and full-year 2025. Q4 revenue was approximately $166.0M (up 11% sequential, +1% YoY). FY2025 revenue was approximately $642.8M, or $598.7M excluding $44.1M of patent litigation settlement payments, a 2% decrease year‑over‑year on the adjusted basis. Instruments revenue fell sharply (FY instruments ~$56.8M, -39% YoY). Consumables grew to ~$507.2M for the year (+3% YoY). Cash and marketable securities were about $520M at year end. Company will present at the J.P. Morgan Healthcare Conference on Jan 12, 2026.
CareDx (Nasdaq: CDNA) and 10x Genomics (Nasdaq: TXG) launched ImmuneScape, a multiomics research program to map immune biology in transplant rejection and therapeutic response.
The collaboration will use 10x Xenium spatial and Chromium Flex single cell platforms to profile FFPE biopsy samples at cellular resolution, focusing on antibody-mediated rejection (AMR) and microvascular inflammation (MVI). Insights are intended to support future diagnostic development and to correlate tissue-level immune architecture with clinical outcomes, including response to anti-CD38 therapies.
10x Genomics (Nasdaq: TXG) announced that members of its management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. Pacific Time.
Investors and interested parties can watch a live webcast of the fireside chat via the company's Investors website at https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.
10x Genomics (Nasdaq: TXG), together with Garvan Institute and University of Tokyo, launched the Asia-Pacific Spatial Translational Research Alliance (ASTRA) on November 18, 2025 to build a pan-cancer spatial atlas using the Xenium spatial platform.
ASTRA will map cancer–immune interactions across 2,000 tumor samples, study ten major cancer types with custom Xenium panels, and create regional hubs and shared digital infrastructure to harmonize biospecimens and data across the Asia-Pacific. The consortium is supported by the ASPIRE program and will formally launch at the inaugural ASTRA Conference in Sydney on Nov 19–21, 2025.
10x Genomics (Nasdaq: TXG) said members of its management team will take part in a fireside chat at the Wolfe Research Healthcare Conference 2025 on Tuesday, November 18, 2025 at 11:20 a.m. ET.
Investors can watch a live webcast via the company’s Investors website and an archived replay will be available for at least 30 days after the event.
10x Genomics (NASDAQ: TXG) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $149.0M. Gross margin was 67%, down from 70% a year earlier due to product mix and inventory write-downs. Operating expenses were $132.5M, down 10% year-over-year. Operating loss narrowed to $32.2M and net loss narrowed to $27.5M. Cash and marketable securities were $482.1M, up $35M sequentially. Q4 2025 revenue guidance: $154M–$158M (midpoint implies ~5% sequential growth, ~6% YoY decline).
10x Genomics (NASDAQ: TXG) launched the next generation of its Chromium Flex assay on October 29, 2025, introducing automation-compatible plate-based multiplexing to scale single cell studies.
The assay supports profiling up to 384 samples and 100 million cells per week in a 96-well plate format, claims improved sequencing efficiency and sensitivity from Flex chemistry, and aims to lower per-sample cost while reducing reagent waste. Early access customers at research institutes and pharma report faster throughput and compatibility with liquid-handling automation. New Flex is available globally and targets high-cell and high-sample applications such as CRISPR screens and FFPE translational studies.
10x Genomics (Nasdaq: TXG) and Anthropic announced on October 20, 2025 a collaboration to integrate 10x single cell and spatial analysis tools into Claude for Life Sciences using the Model Context Protocol (MCP).
The integration enables researchers to run common workflows—aligning reads, generating Feature Barcode matrices, clustering and other secondary analyses—via natural-language conversation rather than code, and connects Claude to 10x Cloud Analysis for scalable, large‑scale datasets.
10x Genomics (Nasdaq: TXG) will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 6, 2025. A public conference call and live webcast for analysts and investors will begin at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments and outlook. The news release with results will be posted on the company website before the call. Live audio will be available in the Investors section at https://investors.10xgenomics.com/ and the webcast will be archived for replay for at least 45 days.
10x Genomics (NASDAQ:TXG) has announced a significant research collaboration with CLISEQ Ltd. and the Weizmann Institute to launch the PERIBLOOD clinical trial, investigating single cell RNA sequencing as a non-invasive alternative to bone marrow aspiration for diagnosing blood disorders.
The three-year international study aims to enroll over 1,500 participants across multiple continents, utilizing 10x Genomics' Chromium GEM-X Single Cell technology. The trial builds on technology developed by Professors Liran Shlush and Amos Tanay, which successfully demonstrated MDS diagnosis from peripheral blood.
This groundbreaking research could potentially transform blood disorder diagnostics by replacing invasive bone marrow procedures with simple blood draws, marking one of the first international clinical programs evaluating single cell transcriptomics in real-world applications.